Elevation Point Wealth Partners LLC Has $1.46 Million Stock Position in Becton, Dickinson and Company $BDX

Elevation Point Wealth Partners LLC lifted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 138.5% in the 3rd quarter, HoldingsChannel reports. The fund owned 7,782 shares of the medical instruments supplier’s stock after purchasing an additional 4,519 shares during the period. Elevation Point Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $1,457,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. EagleClaw Capital Managment LLC boosted its stake in Becton, Dickinson and Company by 8.3% during the 3rd quarter. EagleClaw Capital Managment LLC now owns 32,116 shares of the medical instruments supplier’s stock valued at $6,011,000 after purchasing an additional 2,461 shares during the last quarter. Clifford Capital Partners LLC increased its holdings in Becton, Dickinson and Company by 65.9% during the 3rd quarter. Clifford Capital Partners LLC now owns 123,310 shares of the medical instruments supplier’s stock worth $23,080,000 after purchasing an additional 48,995 shares in the last quarter. Cinctive Capital Management LP raised its stake in shares of Becton, Dickinson and Company by 71.6% in the third quarter. Cinctive Capital Management LP now owns 16,847 shares of the medical instruments supplier’s stock worth $3,153,000 after purchasing an additional 7,028 shares during the last quarter. Circle Wealth Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 47.5% in the third quarter. Circle Wealth Management LLC now owns 4,902 shares of the medical instruments supplier’s stock valued at $918,000 after purchasing an additional 1,579 shares in the last quarter. Finally, Community Bank N.A. lifted its holdings in shares of Becton, Dickinson and Company by 56.7% in the third quarter. Community Bank N.A. now owns 5,037 shares of the medical instruments supplier’s stock valued at $943,000 after purchasing an additional 1,822 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Down 0.2%

BDX stock opened at $159.32 on Monday. The stock’s fifty day simple moving average is $190.01 and its two-hundred day simple moving average is $189.97. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The stock has a market cap of $45.36 billion, a P/E ratio of 25.99, a P/E/G ratio of 11.55 and a beta of 0.24.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.81 by $0.10. The firm had revenue of $5.25 billion during the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The business’s revenue was up 1.6% compared to the same quarter last year. During the same period last year, the firm posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its shares are undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a dividend of $1.05 per share. The ex-dividend date is Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.6%. Becton, Dickinson and Company’s dividend payout ratio is presently 68.52%.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director owned 36,763 shares of the company’s stock, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,416 shares of company stock valued at $674,693 in the last 90 days. 0.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BDX. TD Cowen upped their price target on Becton, Dickinson and Company from $183.00 to $189.00 and gave the stock a “hold” rating in a report on Wednesday, February 11th. JPMorgan Chase & Co. cut their price objective on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a report on Tuesday, February 10th. Royal Bank Of Canada set a $172.00 target price on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Finally, Bank of America raised their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday, January 5th. Five research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $195.46.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.